214 related articles for article (PubMed ID: 10447573)
1. Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts.
Smith JP; Kanekal S; Patawaran MB; Chen JY; Jones RE; Orenberg EK; Yu NY
Cancer Chemother Pharmacol; 1999; 44(4):267-74. PubMed ID: 10447573
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts.
Smith JP; Stock E; Orenberg EK; Yu NY; Kanekal S; Brown DM
Anticancer Drugs; 1995 Dec; 6(6):717-26. PubMed ID: 8845483
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice.
Yu NY; Orenberg EK; Luck EE; Brown DM
Cancer Chemother Pharmacol; 1995; 36(1):27-34. PubMed ID: 7720172
[TBL] [Abstract][Full Text] [Related]
4. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo.
Yu NY; Patawaran MB; Chen JY; Orenberg EK; Brown DM; Luck EE
Cancer J Sci Am; 1995; 1(3):215-21. PubMed ID: 9166479
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer therapy with a novel pump for controlled drug release.
Haramoto M; Kohno M; Nakajima O; Horibe T; Kiyohara M; Fukazawa H; Togawa T; Kawakami K
Oncol Rep; 2010 Feb; 23(2):365-70. PubMed ID: 20043096
[TBL] [Abstract][Full Text] [Related]
6. Organ distribution of 5-fluorouracil loaded gelatine microspheres in mice.
Hao X; Cheng G; Zou M; Sun J; Cui F
Pharmazie; 2004 Sep; 59(9):709-12. PubMed ID: 15497754
[TBL] [Abstract][Full Text] [Related]
7. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel.
Miller BH; Shavin JS; Cognetta A; Taylor RJ; Salasche S; Korey A; Orenberg EK
J Am Acad Dermatol; 1997 Jan; 36(1):72-7. PubMed ID: 8996264
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil.
Chen W; Wu Z; Yang H; Guo S; Li D; Cheng L
Pharm Dev Technol; 2014 Mar; 19(2):223-31. PubMed ID: 23432601
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma.
Kraus S; Miller BH; Swinehart JM; Shavin JS; Georgouras KE; Jenner DA; Griffin E; Korey A; Orenberg EK
J Am Acad Dermatol; 1998 Mar; 38(3):438-42. PubMed ID: 9520026
[TBL] [Abstract][Full Text] [Related]
12. Locally-applied 5-fluorouracil-loaded slow-release patch prevents pancreatic cancer growth in an orthotopic mouse model.
Shim IK; Yi HJ; Yi HG; Lee CM; Lee YN; Choi YJ; Jeong SY; Jun E; Hoffman RM; Cho DW; Kim SC
Oncotarget; 2017 Jun; 8(25):40140-40151. PubMed ID: 28498800
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
Ning S; Trisler K; Brown DM; Yu NY; Kanekal S; Lundsten MJ; Knox SJ
Radiother Oncol; 1996 May; 39(2):179-89. PubMed ID: 8735485
[TBL] [Abstract][Full Text] [Related]
14. Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study.
Puri R; Jain S
Anticancer Drugs; 2012 Oct; 23(9):923-34. PubMed ID: 22926258
[TBL] [Abstract][Full Text] [Related]
15. [The effect of blood-pancreatic juice barrier on 5-fluorouracil in post-pancreatoduodenectomy patients].
Zhao Y; Liao Q; Zhu Z; Fu Q; Cai L; Zhu Y
Zhonghua Wai Ke Za Zhi; 1999 Mar; 37(3):144-5. PubMed ID: 11829804
[TBL] [Abstract][Full Text] [Related]
16. Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study.
Chandrashekar NS; Shobha Rani RH
J BUON; 2007; 12(4):529-34. PubMed ID: 18067212
[TBL] [Abstract][Full Text] [Related]
17. Drug retention following intravesical delivery of fluorouracil therapeutic adhesive in C3H mouse bladder.
Singh SS; Smith KM; Brown DM
Anticancer Drugs; 1996 Jul; 7(5):507-13. PubMed ID: 8862715
[TBL] [Abstract][Full Text] [Related]
18. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies.
Swinehart JM; Skinner RB; McCarty JM; Miller BH; Tyring SK; Korey A; Orenberg EK
Genitourin Med; 1997 Dec; 73(6):481-7. PubMed ID: 9582466
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
20. [Comparison between intraperitoneal and intravenous 5-fluorouracil administration using pancreatic cancer model of nude mouse].
Maruyama M; Yuasa Y; Endo M
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1785-8. PubMed ID: 9382533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
